- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
FDA Clears Enhanced Mobile CT System with High-Resolution Photon-Counting Technology
Photon-counting CT-optimized features with the OmniTom Elite system include 30 cm field of view scanning, continuous spiral scanning, and an ultra-high-resolution capability of 0.141 mm resolution.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the latest version of the OmniTom Elite system, which has been enhanced with photon-counting CT (PCCT) technology.
The PCCT-optimized features of the device range from advanced image processing and an expanded scope of scanning to helical scanning capability, according to NeuroLogica, a subsidiary of Samsung that manufactures the OmniTom Elite system.
The enhanced OmniTomElite computed tomography (CT) system offers a variety of photon-counting CT features including an ultra-high resolution mode with 0.141 mm resolution and expanded scanning to capture a 30 cm field of view. (Image courtesy of NeuroLogica.)
NeuroLogica said key benefits include access to 0.141 mm resolution with the system’s ultra-high resolution mode, post-reconstruction features such as bone removal and virtual non-contrast, continuous spiral scanning capability and expanded scanning to capture a 30 cm field of view.
“With these new features, the OmniTom® Elite PCD not only offers exquisite image quality and diagnostic capabilities but also ensures a more versatile and efficient imaging process. This is a significant advancement for point-of-care imaging, continuing our commitment to enable clinicians to make a more confident diagnosis due to the improved clinical information,” noted Renaud Maloberti, the vice president and head of mCT business at NeuroLogica.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
